Palavras-chave
lncRNA
Prognóstico
Resistência
GAS5
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Identificar lncRNAs associados à resistência à quimioterapia no câncer cervical (CC). Métodos: O estudo é uma revisão sistemática de literatura conduzida de acordo com as diretrizes do Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), o protocolo foi previamente registrado no International Prospective Register of Systematic Reviews (PROSPERO) sob o código CRD42023432017 com buscas realizadas em bases de dados como PubMed, ScienceDirect e Web of Science, resultando na seleção de 21 artigos publicados entre 2017 e 2023. Resultados: Os achados destacaram que 19 lncRNAs estão implicados na resistência a quatro agentes quimioterápicos, incluindo o GAS5, que foi o alvo de um maior número de estudos. Esses lncRNAs estão envolvidos na resistência ao paclitaxel (PTX), ao 5-fluorouracil (5-FU) e à doxorrubicina (DTX). Considerações finais: Esses resultados ressaltam a importância dos lncRNAs como potenciais marcadores de resposta ao tratamento e sugerem que a regulação por miRNAs pode influenciar diretamente vias biológicas frequentemente desreguladas no câncer.
Referências
BHATTACHARJEE R, et al. Cellular landscaping of cisplatin resistance in cervical cancer. Biomed Pharmacother, 2022; 153: 113345.
BRAY F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68(6): 394–424.
BRANDÃO HN, et al. Química e farmacologia de quimioterápicos antineoplásicos derivados de plantas. Quim Nova, 2010; 33(6): 1359–69.
CAO S, et al. Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer. Int J Clin Exp Pathol, 2014; 7(10): 6776–83.
CHEN W, et al. Nomogram for prognosis of elderly patients with cervical cancer who receive combined radiotherapy. Sci Rep, 2023; 13(1): 13299.
DU Y, et al. LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis. BMC Cancer, 2022; 22(1): 1145.
FANG X, et al. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis, 2020; 11(7): 531.
FARZANEH M, et al. Emerging roles of the long non-coding RNA NEAT1 in gynecologic cancers. J Cell Commun Signal, 2023; 17(3): 531–47.
FENG L-L, et al. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity. Gene, 2019; 696: 105–12.
GHOSH S. Cisplatin: The first metal based anticancer drug. Bioorg Chem, 2019; 88: 102925.
GIDDINGS EL, et al. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nat Commun, 2021; 12(1): 2804.
HE J, et al. Long non-coding RNA in cervical cancer: From biology to therapeutic opportunity. Biomed Pharmacother, 2020; 127: 110209.
HE S, et al. The role of the SOX9/lncRNA ANXA2P2/miR-361-3p/SOX9 regulatory loop in cervical cancer cell growth and resistance to cisplatin. Front Oncol, 2021; 11: 784525.
INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2023.
JOHNSON CA, et al. Cervical cancer: An overview of pathophysiology and management. Semin Oncol Nurs, 2019; 35(2): 166–74.
LIU M, et al. Expression of micro-RNA-492 (MiR-492) in human cervical cancer cell lines is upregulated by transfection with wild-type P53, irradiation, and 5-fluorouracil treatment in vitro. Med Sci Monit, 2018; 24: 7750–8
.
LIU MY, LI N. The diagnostic value of lncRNA HOTAIR for cervical carcinoma in vaginal discharge and serum. Medicine (Baltimore), 2023; 102(26): e34042.
LIU S, et al. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett, 2022; 528: 16–30.
LUO X, et al. Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int, 2019; 19: 323.
MAO B-D, et al. LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. J Biosci, 2019; 44(2).
MARKMAN M. Advances in cervical cancer pharmacotherapies. Expert Rev Clin Pharmacol, 2014; 7(2): 219–23.
MECENAS P, et al. Effects of temperature and humidity on the spread of COVID-19: A systematic review. PLoS One, 2020; 15(9): e0238339.
METHLEY AM, et al. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res, 2014; 14(1): 579.
MODABBER N, et al. Evaluation of long non-coding RNA (lncRNA) in the pathogenesis of chemotherapy resistance in cervical cancer: diagnostic and prognostic approach. Mol Biotechnol, 2024; 66(10): 2751–2763.
ORGANIZAÇÃO PAN-AMERICANA DA SAÚDE (OPAS). Câncer do colo do útero. Washington, DC: OPAS.
PAGE MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021; 372: n71.
PAVLOVA NN, THOMPSON CB. The emerging hallmarks of cancer metabolism. Cell Metab, 2016; 23(1): 27–47.
QU S, et al. MiR-361-3p regulates liver tumor-initiating cells expansion and chemo-resistance. J Cancer, 2021; 12(5): 1483–92.
SAW PE, et al. Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci, 2021; 64(1): 22–50.
SETHY C, KUNDU CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother, 2021; 137: 111285.
SHAO X, et al. Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical cancer cells through de-repressing the microRNA-34a/LDHA axis. Biosci Rep, 2021; 41(7).
SHEN C-J, et al. LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target, 2017; 25(7): 637–44.
SWEEF O, et al. Decoding lncRNA in COPD: unveiling prognostic and diagnostic power and their driving role in lung cancer progression. Int J Mol Sci, 2024; 25(16): 9001.
WAN S, ZHAO H. Analysis of diagnostic and prognostic value of lncRNA MEG3 in cervical cancer. Oncol Lett, 2020; 20(5): 183.
WEN Q, et al. Long noncoding RNA GAS5, which acts as a tumor suppressor via microRNA 21, regulates cisplatin resistance expression in cervical cancer. Int J Gynecol Cancer, 2017; 27(6): 1096–108.
YAO T, et al. Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21. J Cell Physiol, 2019; 234(6): 9605–15.
YUAN LY, et al. Involvement of NEAT1/miR-133a axis in promoting cervical cancer progression via targeting SOX4. J Cell Physiol, 2019; 234(10): 18985–18993.
ZHANG L, et al. LncRNA SNHG5 promotes cervical cancer progression by regulating the miR-132/SOX4 pathway. Autoimmunity, 2021; 54(2): 88–96.
ZHANG W, et al. LncRNA HOTAIR promotes chemoresistance by facilitating epithelial to mesenchymal transition through miR-29b/PTEN/PI3K signaling in cervical cancer. Cells Tissues Organs, 2022; 211(1): 16–29.
ZHANG Y, WEN Y. The role of lncRNA NEAT1 in gastric cancer: tumor development and potential therapeutic target. Curr Pharm Des, 2023; 29(28): 2213–22.
ZHOU C, et al. Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): A phase 3, open-label, randomized controlled trial. J Thorac Oncol, 2023; 18(1): 93–105.